Nasdaq
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. The company also provides related technology- enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Roles derived from SEC Form 4 filings.
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $243.5M | $286.1M | $335.6M | $354.3M | $385.1M | $418.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$24.4M | $13.6M | $32.5M | -$40.8M | -$1.7M | $21.0M |
| Net income | -$49.4M | -$13.3M | $14.7M | -$55.4M | -$12.1M | -$1.6M |
| Diluted EPS | -$0.37 | -$0.09 | $0.09 | -$0.35 | -$0.08 | -$0.01 |
| Operating cash flow | $44.8M | $60.4M | $92.5M | $82.8M | $80.5M | $96.3M |
| Free cash flow | $43.9M | $59.2M | $91.1M | $81.0M | $78.8M | $94.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -10.0% | 4.7% | 9.7% | -11.5% | -0.4% | 5.0% |
| Net margin | -20.3% | -4.6% | 4.4% | -15.6% | -3.1% | -0.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $93.3M | $94.8M | $100.4M | $106.0M | $104.6M | $104.6M | $103.6M | $106.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$9.0M | $2.6M | $6.0M | $7.6M | $9.6M | $3.0M | $836,000.00 | -$4.3M |
| Net income | -$12.6M | -$1.4M | $6.6M | $4.7M | -$2.0M | $1.5M | -$5.9M | -$8.8M |
| Diluted EPS | -$0.08 | -$0.01 | $0.04 | $0.03 | -$0.01 | $0.01 | -$0.04 | -$0.06 |
| Operating cash flow | $9.8M | $17.0M | $49.4M | $17.4M | $17.8M | $32.3M | $28.8M | $11.7M |
| Free cash flow | $9.4M | $16.8M | $49.0M | $16.8M | $17.8M | $32.1M | $27.8M | $11.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -9.7% | 2.7% | 6.0% | 7.2% | 9.1% | 2.9% | 0.8% | -4.0% |
| Net margin | -13.5% | -1.4% | 6.6% | 4.5% | -1.9% | 1.5% | -5.7% | -8.2% |
Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-01 | Corcoran Daniel· SVP and General Counsel | Tax withholding | 7,893 | $5.82 | $45,937.26 | filing |
| 2026-06-01 | Corcoran Daniel· SVP and General Counsel | Tax withholding | 4,210 | $5.82 | $24,502.20 | filing |
| 2026-06-01 | Anhalt Rona· Chief Human Resources Officer | Tax withholding | 2,241 | $5.82 | $13,042.62 | filing |
| 2026-06-01 | Anhalt Rona· Chief Human Resources Officer | Option exercise | 7,147 | $0.00 | $0.00 | filing |
| 2026-06-01 | Corcoran Daniel· SVP and General Counsel | Option exercise | 14,889 | $0.00 | $0.00 | filing |
| 2026-06-01 | Corcoran Daniel· SVP and General Counsel | Option exercise | 7,941 | $0.00 | $0.00 | filing |
| 2026-05-14 | Crane Rosemary A | Option exercise | 15,757 | $0.00 | $0.00 | filing |
| 2026-05-14 | WALSH MATTHEW M | Option exercise | 15,757 | $0.00 | $0.00 | filing |
| 2026-05-14 | BROSHY ERAN | Option exercise | 15,757 | $0.00 | $0.00 | filing |
| 2026-05-14 | Collins Cynthia | Option exercise | 15,757 | $0.00 | $0.00 | filing |
| 2026-05-14 | Reynders John V W· Chief Financial Officer | Option exercise | 15,757 | $0.00 | $0.00 | filing |
| 2026-05-14 | Bedi Arjun | Option exercise | 5,547 | $0.00 | $0.00 | filing |
| 2026-05-14 | CASHMAN JAMES E III | Option exercise | 15,757 | $0.00 | $0.00 | filing |
| 2026-05-14 | Killefer Nancy | Option exercise | 15,757 | $0.00 | $0.00 | filing |
| 2026-05-11 | Resnick Jon Matthew· Chief Executive Officer | Tax withholding | 24,377 | $6.31 | $153,818.87 | filing |
| 2026-05-11 | Resnick Jon Matthew· Chief Executive Officer | Option exercise | 59,766 | $0.00 | $0.00 | filing |
| 2026-04-01 | Gallagher John E· Chief Financial Officer | Tax withholding | 7,803 | $5.70 | $44,477.10 | filing |
| 2026-04-01 | Gallagher John E· Chief Financial Officer | Tax withholding | 7,775 | $5.70 | $44,317.50 | filing |
| 2026-04-01 | Aspbury Robert· PRESIDENT, PREDICTIVE TECH | Tax withholding | 7,139 | $5.70 | $40,692.30 | filing |
| 2026-04-01 | Aspbury Robert· PRESIDENT, PREDICTIVE TECH | Tax withholding | 6,821 | $5.70 | $38,879.70 | filing |
| 2026-04-01 | Corcoran Daniel· SVP and General Counsel | Tax withholding | 5,751 | $5.70 | $32,780.70 | filing |
| 2026-04-01 | Gallagher John E· Chief Financial Officer | Tax withholding | 5,203 | $5.70 | $29,657.10 | filing |
| 2026-04-01 | Aspbury Robert· PRESIDENT, PREDICTIVE TECH | Tax withholding | 4,760 | $5.70 | $27,132.00 | filing |
| 2026-04-01 | Pedersen Leif E· PRESIDENT, CHIEF COMMERCAL OFF | Tax withholding | 3,699 | $5.70 | $21,084.30 | filing |
| 2026-04-01 | Aspbury Robert· PRESIDENT, PREDICTIVE TECH | Tax withholding | 3,691 | $5.70 | $21,038.70 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.